Cargando…
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718360/ https://www.ncbi.nlm.nih.gov/pubmed/34973713 http://dx.doi.org/10.1016/S0140-6736(21)02657-X |
| _version_ | 1784624708003561472 |
|---|---|
| author | Heskin, Joseph Pallett, Scott J C Mughal, Nabeela Davies, Gary W Moore, Luke S P Rayment, Michael Jones, Rachael |
| author_facet | Heskin, Joseph Pallett, Scott J C Mughal, Nabeela Davies, Gary W Moore, Luke S P Rayment, Michael Jones, Rachael |
| author_sort | Heskin, Joseph |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8718360 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87183602022-01-03 Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management Heskin, Joseph Pallett, Scott J C Mughal, Nabeela Davies, Gary W Moore, Luke S P Rayment, Michael Jones, Rachael Lancet Correspondence Elsevier Ltd. 2022 2021-12-31 /pmc/articles/PMC8718360/ /pubmed/34973713 http://dx.doi.org/10.1016/S0140-6736(21)02657-X Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Heskin, Joseph Pallett, Scott J C Mughal, Nabeela Davies, Gary W Moore, Luke S P Rayment, Michael Jones, Rachael Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management |
| title | Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management |
| title_full | Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management |
| title_fullStr | Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management |
| title_full_unstemmed | Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management |
| title_short | Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management |
| title_sort | caution required with use of ritonavir-boosted pf-07321332 in covid-19 management |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718360/ https://www.ncbi.nlm.nih.gov/pubmed/34973713 http://dx.doi.org/10.1016/S0140-6736(21)02657-X |
| work_keys_str_mv | AT heskinjoseph cautionrequiredwithuseofritonavirboostedpf07321332incovid19management AT pallettscottjc cautionrequiredwithuseofritonavirboostedpf07321332incovid19management AT mughalnabeela cautionrequiredwithuseofritonavirboostedpf07321332incovid19management AT daviesgaryw cautionrequiredwithuseofritonavirboostedpf07321332incovid19management AT moorelukesp cautionrequiredwithuseofritonavirboostedpf07321332incovid19management AT raymentmichael cautionrequiredwithuseofritonavirboostedpf07321332incovid19management AT jonesrachael cautionrequiredwithuseofritonavirboostedpf07321332incovid19management |